{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Filtering repoDB to find successful and failed drug repurposing \n",
    "\n",
    "Data from http://apps.chiragjpgroup.org/repoDB/\n",
    "\n",
    "Information about terms available here\n",
    "https://clinicaltrials.gov/ct2/about-studies/glossary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import collections\n",
    "import re\n",
    "\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drug_name</th>\n",
       "      <th>drug_id</th>\n",
       "      <th>ind_name</th>\n",
       "      <th>ind_id</th>\n",
       "      <th>NCT</th>\n",
       "      <th>status</th>\n",
       "      <th>phase</th>\n",
       "      <th>DetailedStatus</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>DB00001</td>\n",
       "      <td>Heparin-induced thrombocytopenia with thrombosis</td>\n",
       "      <td>C0272275</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>DB00002</td>\n",
       "      <td>Squamous cell carcinoma of mouth</td>\n",
       "      <td>C0585362</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Approved</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   drug_name  drug_id                                          ind_name  \\\n",
       "0  Lepirudin  DB00001  Heparin-induced thrombocytopenia with thrombosis   \n",
       "1  Cetuximab  DB00002                  Squamous cell carcinoma of mouth   \n",
       "\n",
       "     ind_id  NCT    status phase DetailedStatus  \n",
       "0  C0272275  NaN  Approved   NaN            NaN  \n",
       "1  C0585362  NaN  Approved   NaN            NaN  "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.read_csv('repoDB.csv')\n",
    "\n",
    "success_df = df.query('status == \"Approved\"').assign(label=1)\n",
    "fail_df = df.query('status != \"Approved\"').assign(label=0)\n",
    "\n",
    "df.head(2)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Imperfect manual curation of function failures\n",
    "\n",
    "Many clinical trials are not completed due to administrative reasons, such as a failure to recruit participants. These should be filtered as the actual treatment effect remains unknown."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "fail_df['functional_failure'] = (fail_df['DetailedStatus']\n",
    ".apply(lambda x: \n",
    "       not pd.isna(x)\n",
    "       and 'complete' not in str(x).lower()\n",
    "       and 'accru' not in str(x).lower()  # accrual and accrue\n",
    "       and 'enrol' not in str(x).lower()\n",
    "       and 'fund' not in str(x).lower()\n",
    "       and 'recruit' not in str(x).lower()\n",
    "       and 'availab' not in str(x).lower()\n",
    "       and 'pi' not in str(x).lower()\n",
    "       and 'p.i.' not in str(x).lower()\n",
    "       and 'insurance' not in str(x).lower()\n",
    "       and 'competitor' not in str(x).lower()\n",
    "       and 'business' not in str(x).lower()\n",
    "       and 'supply' not in str(x).lower()\n",
    "       and 'access' not in str(x).lower()\n",
    "       and 'eligib' not in str(x).lower()\n",
    "       and 'admin' not in str(x).lower()\n",
    "       and 'license' not in str(x).lower()\n",
    "       and x != 'withdrawn'\n",
    "       and x != 'New study written'\n",
    "       and x != 'drug now on market'\n",
    "      )\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('Temporarily stopped for assessment', 50),\n",
       " ('Major revisions needed in study', 48),\n",
       " ('Financial Sponsor requested termination', 36),\n",
       " ('This study will not be written up.', 35),\n",
       " ('Discontinued development of G3139 (oblimersen)', 20),\n",
       " ('due to safety concerns and lack of efficacy', 16),\n",
       " ('Unacceptable morbidity & mortality', 12),\n",
       " ('Increased rate of bacterial infections', 10),\n",
       " ('Sponsor withdrew support; Study did not progress to Phase II.', 9),\n",
       " ('Trial was terminated to allow sponsors to evaluate the future development of the drug program',\n",
       "  9),\n",
       " ('Sponsor withdrew support; Study did not progress to Phase II (Phase I registration    NCT00895960)',\n",
       "  9),\n",
       " ('The study was not activated.', 8),\n",
       " ('See termination reason in detailed description.', 8),\n",
       " ('Extreme toxicity of Pertuzumab and Erlotinib combination', 8),\n",
       " ('The study was stopped due to the inability to determine an acceptable dose with the potential    for further study',\n",
       "  8),\n",
       " ('Data from the C08 study and Avant study', 7),\n",
       " ('See termination reason in detailed description', 7),\n",
       " ('This study was closed early by the DSMB due to increased toxicity.', 7),\n",
       " ('See Detailed Description', 6),\n",
       " ('inactive', 6),\n",
       " ('Withdrawn by the study sponsor.', 6),\n",
       " ('Company decided to stop development of drug - 7/31/12', 6),\n",
       " ('Research Cancelled', 6),\n",
       " ('No progression of Phase 1 trial to Phase 2.', 6),\n",
       " ('Temporarily stopped for assessment. Contact ctsucontact@westat.com for specifics',\n",
       "  6),\n",
       " ('Temporarily stopped for assessment.', 6),\n",
       " ('Terminated due to bevacizumab and chemoradiotherapy toxicity', 5),\n",
       " ('Terminated', 5),\n",
       " ('Terminated by Sponsor', 5),\n",
       " ('Investigator decision', 5),\n",
       " ('Objectives not met.', 5),\n",
       " ('Study closed by the NCI.', 4),\n",
       " ('Closed due to competing protocols', 4),\n",
       " ('It was unlikely that the primary endpoint would be reached based on the fifth interim analysis    results.',\n",
       "  4),\n",
       " ('IRB Study Closure', 4),\n",
       " ('MTD not determined', 4),\n",
       " ('The major and primary reason for the study termination is the observed reduced efficacy of    CellCept compared to placebo.',\n",
       "  4),\n",
       " ('Terminated due to withdrawal of support from our collaborator.', 4),\n",
       " ('ONTAK has been pulled off the market for further testing. Subsequently, EISAI will no longer    be supporting clinical trials that utilize this drug.',\n",
       "  4),\n",
       " ('Interim analysis', 4),\n",
       " ('Study is no longer required by Brazil health authority.', 4),\n",
       " ('Manufacturer discontinued drug development.', 4),\n",
       " ('Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche    (Ireland).',\n",
       "  4),\n",
       " ('The company (Enzon Pharmaceuticals)providing the drug EZN-3042 decided to end its development    of EZN-3042.',\n",
       "  4),\n",
       " ('lack of personnel resource and protocol amendment needed', 4),\n",
       " ('Unexpected toxicities, likely due to TIL/IL-12 & low % of durable responses.',\n",
       "  4),\n",
       " (\"Per sponsor's decision\", 4),\n",
       " ('efficacy interim analysis as per protocol', 4),\n",
       " ('Feasibility of the trial was proven to be absent.', 4),\n",
       " ('Due to potential competition with a post-marketing study requested by FDA',\n",
       "  4),\n",
       " ('Study on hold due to primary co-investigator leaving the institution.', 4),\n",
       " ('safety reasons', 3),\n",
       " ('Toxicity', 3),\n",
       " ('The study was terminated prior to completion to focus on the development of a controlled    release formulation.',\n",
       "  3),\n",
       " ('Sponsor decision', 3),\n",
       " ('wothdrawal of sponsor', 3),\n",
       " ('short of participants', 3),\n",
       " ('Safety reasons', 3),\n",
       " ('unexpected level of toxicity', 3),\n",
       " ('Negative sorafenib results from ESCAPE trial and safety concerns of regimen',\n",
       "  3),\n",
       " ('data analysis showed insufficient drug efficacy', 3),\n",
       " ('DSMB stopped study because placebo arm had more adverse events', 3),\n",
       " ('Based on data collected, the combination appeared to be poorly tolearated.',\n",
       "  3),\n",
       " ('Terminated due to failure to meet the primary efficacy endpoint in the Short-term Period',\n",
       "  3),\n",
       " ('never been started', 3),\n",
       " ('No patients exhibited natural killer cell expansion (primary endpoint).',\n",
       "  3),\n",
       " ('Closed early due to determination of futility/efficacy.', 3),\n",
       " ('High patient withdrawal rate', 3),\n",
       " (\"Data Safety Monitoring Board concerning of the participants' safety\", 3),\n",
       " ('Terminated by sponsor due to new unpublished data that rendered the current design of the    study no longer clinically relevant. There were no safety concerns.',\n",
       "  3),\n",
       " ('Study will not be intiated', 3),\n",
       " ('The study was prematurely terminated because of unavailibility of Methylnaltrexone in the    region',\n",
       "  3),\n",
       " ('Doxil Shortage', 3),\n",
       " ('The Sponsor has no interest in continuing the study.', 3),\n",
       " ('IT was impossible to find patients', 3),\n",
       " ('Study only randomized 1 subject and was determined not feasible by DSMB',\n",
       "  3),\n",
       " ('Refer to Detailed Description for documentaion of Termination Statement.',\n",
       "  3),\n",
       " ('Due to safety concern of active control drug', 3),\n",
       " ('Sponsor seeking additional financial support before starting the study', 3),\n",
       " ('On 05/08/12, team working on revising protocol and re-open study under version 2.0',\n",
       "  3),\n",
       " ('Non-compliance', 3),\n",
       " ('Too slow patient inclusion and superior effect of the injection', 3),\n",
       " ('DSMB recommended closing the study and publishing the results', 2),\n",
       " ('Interim analysis indicated study should be terminated', 2),\n",
       " ('Preliminary results showed increased intraventricular hemorrhage (IVH) in experimental arm',\n",
       "  2),\n",
       " ('Not opened at Fox Chase Cancer Center', 2),\n",
       " ('Terminated in view of the C107 findings demonstrating efficacy at doses of 90 and 30 minutes',\n",
       "  2),\n",
       " ('The unpromising experience of the French group with topotecan given at a dosage of 0.4    mg/m2/day over 30 mins w/in 1 hr of radiation (Cancer 2005; 104: 2792).',\n",
       "  2),\n",
       " ('Interim analysis showed the primary outcome was not reached', 2),\n",
       " ('Program discontinued', 2),\n",
       " ('The study was discontinued due to the death of a co-investigator and a second co-investigator    leaving the institution.',\n",
       "  2),\n",
       " ('This was a follow-on study to Biomed 777-CLP-029 which did not meet superiority endpoint',\n",
       "  2),\n",
       " ('FDA Hold May 2007', 2),\n",
       " ('Insufficient evidence of the clinical effectiveness of cangrelor', 2),\n",
       " ('Vaccine sponsor ceased operations.', 2),\n",
       " ('Sponsor Decision', 2),\n",
       " ('Terminated, new protocol to be developed', 2),\n",
       " ('Refer to Detailed Description.', 2),\n",
       " ('Study Terminated; Commitment met per Regulatory Authorities.', 2),\n",
       " ('Halted by NICHD after recommendation by DSMC to stop for futility', 2),\n",
       " ('pts. will be captured in core', 2),\n",
       " ('side effect profile did not match expectations', 2),\n",
       " ('Company decision has been taken in light of recent demands by certain national health    authorities',\n",
       "  2),\n",
       " ('The perceived risk-benefit ratio for individuals with early active RA', 2),\n",
       " ('The study withdrawn due to lack financial support', 2),\n",
       " ('Local pharmacy unwilling to comply with study protocol', 2),\n",
       " ('Carisbamate partial onset seizures studies lacked consistent efficacy data so trials in this    indication were terminated.',\n",
       "  2),\n",
       " ('OncoGel did not show any impact on overall tumor response', 2),\n",
       " ('The study was terminated due to unanticipated safety issues', 2),\n",
       " ('Replaced by another study', 2),\n",
       " (\"Sponsor's decision\", 2),\n",
       " ('Dr. Jorizzo has decided to withdraw from this study due to the time it is taking to get the    study started.',\n",
       "  2),\n",
       " ('Malaria prev. fell in the study area, so we cannot evaluate the primary endpoint',\n",
       "  2),\n",
       " ('financial constraints', 2),\n",
       " ('Investigator no longer at university', 2),\n",
       " ('We are currently performing and interim analysis for possible neonatal organism resistance to    antibiotic regimens.',\n",
       "  2),\n",
       " ('MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.',\n",
       "  2),\n",
       " ('Study has been stopped by sponsor decision', 2),\n",
       " ('The study is terminated prematurely as the sponsor decided to discontinue program with EMD    525797 in oncology.',\n",
       "  2),\n",
       " ('AstraZeneca has discontinued the development of AZD0530. No new AstraZeneca-sponsored clinical    studies will be initiated..',\n",
       "  2),\n",
       " ('Colaborator withdrew support.', 2),\n",
       " ('Study was withdrawn due issuses related to the science', 2),\n",
       " ('toxicities', 2),\n",
       " ('Preliminary data from study NCT00994214 do not support expected inhibition of GH and IGF-1',\n",
       "  2),\n",
       " ('Failed to reach endpoints', 2),\n",
       " ('Preliminary data from this study does not support expected inhibition of GH and IGF-1',\n",
       "  2),\n",
       " ('Study abandoned', 2),\n",
       " ('Lack of patient population', 2),\n",
       " ('Lacking effect of treatment', 2),\n",
       " ('Lost sponsorship for study drug', 2),\n",
       " ('Study was never initiated under new location/provider group. Contract to continue was never    signed between TEVA and Kennedy Headache Center',\n",
       "  2),\n",
       " ('Due to change in the national policy of medications', 2),\n",
       " ('The study was terminated because we were not able to obtain the study drug.',\n",
       "  2),\n",
       " ('abandoned', 2),\n",
       " ('Most potential subjects had already been prescribed Cymbalta.', 2),\n",
       " ('Drug shortage', 2),\n",
       " ('Terminated early in agreement with Health Authorities for feasibility reasons',\n",
       "  2),\n",
       " ('Did not begin', 2),\n",
       " ('Study never undertaken', 2),\n",
       " ('Study is terminated due to lack of efficacy', 2),\n",
       " ('Clinical trial being transferred to Columbia University with the Investigator.',\n",
       "  2),\n",
       " ('Regulatory requirement. A phase III study is being designed.', 2),\n",
       " ('Due to change in development plan.', 2),\n",
       " ('Never initiated. Withdrawn by sponsor.', 2),\n",
       " ('Data did not show that the two biologic treatments impacted PMR disease activity to the same    degree as steroid treatment within a 2-week treatment period.',\n",
       "  2),\n",
       " ('Trial not progressing toward scientific goals', 2),\n",
       " ('Sponsor closed study', 2),\n",
       " ('Institution decided on starting a new protocol of sedation, with another methods and that´s    why this study has not started.',\n",
       "  2),\n",
       " ('Study site has terminated the study due to the complexity of the study', 2),\n",
       " ('Please see Purpose Statement below', 2),\n",
       " ('Recently published data that has shown HCQ to be safe when combined with chemo and or    radiation at even higher doses than what is used in this study.',\n",
       "  2),\n",
       " ('Closed early due to increased hematologic toxicity and possible reduced efficacy',\n",
       "  2),\n",
       " ('Interim analysis shows harma to one of the study arms.', 2),\n",
       " ('Interim analysis of PK and toxicity data', 2),\n",
       " ('HRI no longer conducting research.', 2),\n",
       " ('Diminished rectruitment', 2),\n",
       " ('Outcome of EXPAND study (no benefit from adding cetuximab to the first-line chemotherapy in    advanced gastric cancer in the overall patient population)',\n",
       "  2),\n",
       " ('Previous studies have been done regarding same condition', 2),\n",
       " ('Due to the high rate of morbidity and mortality', 2),\n",
       " ('Due to budget limitations, the company decided to withdraw this study.', 2),\n",
       " ('Material sponsor withdrew support', 2),\n",
       " ('Obtained results were not good. Protocol was proved ineffective.', 2),\n",
       " ('Potential participants had concerns about taking the study drug (methotrexate).',\n",
       "  2),\n",
       " ('Personnel changes at study site.', 2),\n",
       " ('Concerns regarding neonatal data', 1),\n",
       " ('Study design changes were needed based on GIPF-001 results', 1),\n",
       " ('Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have    data.',\n",
       "  1),\n",
       " ('Futility reasons after Independent Data Monitoring Committee interim analysis',\n",
       "  1),\n",
       " ('European reports of liver toxicity from kava meant that the study had to stop',\n",
       "  1),\n",
       " ('Interim analysis, infliximab did not reduce number of first relapses in GCA or cumulative    glucocorticosteroid dosage',\n",
       "  1),\n",
       " ('drug issues', 1),\n",
       " ('insufficient efficacy', 1),\n",
       " ('Study prematurely discont’d 20-Apr-2006 after interim analysis suggested sample size could be    reduced without losing power. No safety concerns led to decision.',\n",
       "  1),\n",
       " ('Pharmaceutical sponsor withdrew financial support.', 1),\n",
       " ('Study was never initiated', 1),\n",
       " ('trial stopped on Sept 24, 2007', 1),\n",
       " ('Study never started.', 1),\n",
       " ('Insufficient power to show therapy difference at interim analysis.', 1),\n",
       " ('difficulty of recrutement', 1),\n",
       " ('Inconsistent treatment benefit', 1),\n",
       " ('No response seen in patients', 1),\n",
       " ('Study was discontinued because of high drop out rate.', 1),\n",
       " ('Non-protocol feasibility', 1),\n",
       " ('This study has been terminated early as the esreboxetine development program is being    discontinued. There are no safety or efficacy concerns.',\n",
       "  1),\n",
       " ('Study stopped because of toxicity concerns.', 1),\n",
       " ('Lack of efficacy', 1),\n",
       " ('Per Group Chair: This study will not move forward.', 1),\n",
       " ('Primary (safety) endpoint reached', 1),\n",
       " ('Withdrawn because protocol has been discontinued. It was never opened.', 1),\n",
       " ('Stopped for futility by DSMB', 1),\n",
       " ('Low Accural', 1),\n",
       " ('Too frequent grade 3-4 toxicities', 1),\n",
       " ('reports indicating that increased folic acid intake may increase colin cancer',\n",
       "  1),\n",
       " ('lack of patients', 1),\n",
       " ('Terminated due to dose limiting toxicity', 1),\n",
       " ('At the end of the year 2002, Cameroon switched from chloroquine to amodiaquine as first-line    therapy for of uncomplicated malaria.',\n",
       "  1),\n",
       " (\"The termination of the study is not linked to a product recall or result of any safety signal.    Rather it was sponsor's commercial decision to withdraw the MA\",\n",
       "  1),\n",
       " ('TRIAL STOPPED due to a change in standard of care and the required patient numbers could no    longer be achieved',\n",
       "  1),\n",
       " ('The primary efficacy endpoint was not met', 1),\n",
       " ('Amgen discontinued the development of AMG706 because 20050201 did not meet its primary    objective.',\n",
       "  1),\n",
       " ('Change of practice pattern. Green light laser', 1),\n",
       " ('The study has finished.', 1),\n",
       " ('Toxicity of combination from other trials', 1),\n",
       " ('change in development plan, not due to safety concerns.', 1),\n",
       " ('IDMC made a recommendation to stop the trial as the target for continuing to the 2nd phase was    not met.',\n",
       "  1),\n",
       " ('Data Monitoring Committee concluded after a planned interim analysis that aflibercept added to    gemcitabine would be unable to demonstrate improved survival',\n",
       "  1),\n",
       " ('Sponsor decision - not related to safety', 1),\n",
       " ('Avastin approved for first-in-line treatment.', 1),\n",
       " ('Study was terminated early due to lack of efficacy.', 1),\n",
       " ('Trial terminated due to financial resource limitations', 1),\n",
       " ('DSMB recommended termination based on interim outcomes analysis', 1),\n",
       " ('Strategic direction of the sponsor changed', 1),\n",
       " ('See Detailed Description field.', 1),\n",
       " ('due to new safety information', 1),\n",
       " ('Study was terminated for futility following the planned interim analysis.',\n",
       "  1),\n",
       " ('Due to changes in portfolio review', 1),\n",
       " ('sufficient number to reach the primary endpoint and as planned', 1),\n",
       " ('Study never opened', 1),\n",
       " ('The interim analysis showed no tendency in favour of the verum group. Therefore it was decided    to stop the study prematurely.',\n",
       "  1),\n",
       " ('Please see Detailed Description for termination reason.', 1),\n",
       " ('Male subjects were terminated due to an imbalance in prostate cancer events',\n",
       "  1),\n",
       " ('Expected mortality rates in placebo and treatment groups lower than predicted',\n",
       "  1),\n",
       " ('This project was not a clinical trial requiring registration', 1),\n",
       " ('Primary endpoint not achieved', 1),\n",
       " (\"Subject recuitment halted and won't resume; subjects are no longer being treated.\",\n",
       "  1),\n",
       " ('Preliminary analysis', 1),\n",
       " ('Interim analysis indicated low probability of clinically significant result',\n",
       "  1),\n",
       " ('Pfizer has terminated the execution of this protocol', 1),\n",
       " ('Principal Investigator decided to close the study early.', 1),\n",
       " ('Modifications will be necessary before full IRB approval will be secured.',\n",
       "  1),\n",
       " ('Drug combination is no longer pursued', 1),\n",
       " ('not yet started', 1),\n",
       " ('IND not obtained', 1),\n",
       " ('Drug no longer being supplied by sponsor', 1),\n",
       " ('Clinical trial terminated due to results from recent nonclinical studies',\n",
       "  1),\n",
       " ('Company decision to modify the ferroquine development strategy; discontinuation not due to    safety or activity unexpected findings',\n",
       "  1),\n",
       " ('Technical/operational issues', 1),\n",
       " ('Excess of mortality in the treatment group created safety concerns.', 1),\n",
       " ('This study was discontinued due to a shown lack of efficacy in the investigational agent',\n",
       "  1),\n",
       " ('the H1N1 pandemic is now over, and fewer cases than expected were observed',\n",
       "  1),\n",
       " ('Completion of dose escalation phase', 1),\n",
       " ('study did not reach benchmark efficacy rule at 16 subjects', 1),\n",
       " ('Study closed Nov 2000 by Amgen, who stopped drug delivery', 1),\n",
       " ('The study is terminated prematurely as the sponsor decided to discontinue program with    Tecemotide in NSCLC.',\n",
       "  1),\n",
       " ('Stopped due to futility.', 1),\n",
       " ('stopped for futility', 1),\n",
       " ('Poor inclusion rate.', 1),\n",
       " ('Changes in approach to PDA therapy', 1),\n",
       " ('Study was terminated due to sponsor portfolio decision.', 1),\n",
       " ('Poor efficacy (2 of 31 completing participants with H.pylori eradication)',\n",
       "  1),\n",
       " ('Sponsor halted study.', 1),\n",
       " ('Interim analysis showed significant effect in favour of full-dose atorvastatin.',\n",
       "  1),\n",
       " ('Terminated based on safety results from another trial', 1),\n",
       " ('Pre-planned interim analysis.', 1),\n",
       " ('The changing aetiology of squamous cell carcinoma of the head and neck (SCCHN).',\n",
       "  1),\n",
       " ('Noted increased risks, greater than expected for standard of care therapy.',\n",
       "  1),\n",
       " ('The objective response rate by more than two people are confirmed.', 1),\n",
       " ('In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety    concerns. As a result, the companion trial, OSI-774-206 has been stopped',\n",
       "  1),\n",
       " ('I am relocating to Johns Hopkins Medical Center', 1),\n",
       " ('sponsor withdraw from this study', 1),\n",
       " ('Original investigator left this institution, replacement investigator retired.',\n",
       "  1),\n",
       " ('Study terminated due to a technical issue (randomization error).', 1),\n",
       " ('Interim analysis showed that the primary endpoint would not be met.', 1),\n",
       " ('change company strategy', 1),\n",
       " ('Inclusion rate not as expected. Not financially possible to involve other centres.',\n",
       "  1),\n",
       " ('The study was treminated because of low accural', 1),\n",
       " ('Interim analysis results revealed substantial increase of patient number, with unfeasible    study prolongation.',\n",
       "  1),\n",
       " ('To be compliant with the timelines as agreed with Paediatric Committee (PC) within the    Paediatric Investigational Plan',\n",
       "  1),\n",
       " ('1 patient died of uncertain cause but possibly related to drug. Regulatory currently reviewing',\n",
       "  1),\n",
       " ('Some of the researchers finished their participation in the study.', 1),\n",
       " ('Lack of adherence and huge loss of follow up.', 1),\n",
       " ('trial design contingent on RFA optimization', 1),\n",
       " ('The trial was early terminated after it was concluded that there was no added benefit from    exposing further participants after an unblinded interim analysis.',\n",
       "  1),\n",
       " ('This study was closed prematurely due study team travel restrictions.', 1),\n",
       " ('Study was not given ethical approval- a alternative protocol required', 1),\n",
       " ('Terminated after placing the study on hold at the request of the FDA', 1),\n",
       " ('Protocol Revisions', 1),\n",
       " ('Unexpected toxicity (2 early deaths)', 1),\n",
       " ('Evidence of very low probability to success. No safety issues.', 1),\n",
       " ('medical/ethical reasons', 1),\n",
       " ('Terminated before starting due to need for IND determined by FDA.', 1),\n",
       " ('Frequent adverse events occurred early in treatment with poor tolerability.',\n",
       "  1),\n",
       " ('Drug toxicity', 1),\n",
       " ('Terminated because primary efficacy parameter failed to demonstrate statistically significant    difference between memantine and placebo in controlled trials',\n",
       "  1),\n",
       " ('Evidence of very low probability to success. No safety issues', 1),\n",
       " ('Study was not approved by Health Surveillance Agency', 1),\n",
       " ('missed endpoint of meaningful clinical benefit, compared to prednisolone 2.7mg',\n",
       "  1),\n",
       " ('GLP-2 Drug product stability concerns', 1),\n",
       " ('Decision taken to halt progression of mefloquine as a potential partner for OZ439 as a single    dose cure due to low probability of success',\n",
       "  1),\n",
       " ('Substantial benefit was observed in the active treatment group', 1),\n",
       " ('Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam',\n",
       "  1),\n",
       " ('FDA placed a clinical hold on the Pediatric Program requiring retigabine discontinuation in    subjects; early termination allows for timely reporting of results.',\n",
       "  1),\n",
       " ('Change in clinical strategy.', 1),\n",
       " ('Study transferring to another facility', 1),\n",
       " ('low inclusion', 1),\n",
       " ('awaiting FDA approval for next dose group', 1),\n",
       " ('withdrawn by industry', 1),\n",
       " ('Lack of efficacy with one month of treatement', 1),\n",
       " ('H1N1 pandemic concluded', 1),\n",
       " ('difficulties to include patients', 1),\n",
       " ('Unable to secure drug.', 1),\n",
       " ('Because the inclusion rate was lower than expected.', 1),\n",
       " ('Based on the previous study results, inactivated EV71 vaccine with aluminum adjuvant was    elected to be used for the efficacy Phase III study.',\n",
       "  1),\n",
       " ('Study was closed due to recommendations of performing a PK study first.',\n",
       "  1),\n",
       " ('Telaprevir will not be used in NL, no more inclusions are expected.', 1),\n",
       " ('Protocol modification', 1),\n",
       " ('because a significant decrease of viable candidates for the study.', 1),\n",
       " ('company stopped production of study drug due to excessive toxicities', 1),\n",
       " ('Strategic decision not to proceed with the opening of this study. There are no concerns over    the safety or quality of the investigational products involved.',\n",
       "  1),\n",
       " ('drug company withdrww support following a re-examination of the benefit-risk assessment for    the investigational use of imetelstat in this population',\n",
       "  1),\n",
       " ('Major amendment - change in design', 1),\n",
       " ('The DSMB conducted an interim analysis on overall survival, which showed that the treatment    arm did not demonstrate a sufficient improvement in OS vs. placebo.',\n",
       "  1),\n",
       " ('Low cure rate in the study (fluconazole) group', 1),\n",
       " ('Investigator is leaving the institution.', 1),\n",
       " ('Lack of Efficacy', 1),\n",
       " ('Closed by sponsor', 1),\n",
       " ('Drug reformulation', 1),\n",
       " (\"DSMB's decision following the first step analysis\", 1),\n",
       " ('Study terminated due to lack of efficacy', 1),\n",
       " ('Publication of recent trials showing no effect of EPO in TBI substantially reduced equipoise    about this study.',\n",
       "  1),\n",
       " ('All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data    Monitoring Committee safety review of study 20070622.',\n",
       "  1),\n",
       " ('occurrence of a serious adverse event', 1),\n",
       " ('Principle Investigator is moving to another institution and plans to restart this proctocol in    the new location.',\n",
       "  1),\n",
       " ('Lack of internal resources', 1),\n",
       " ('the study was not feasible', 1),\n",
       " ('Discrepancies in medication orders', 1),\n",
       " ('Company decision', 1)]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "collections.Counter(fail_df[fail_df['functional_failure'] == True]['DetailedStatus']).most_common()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "repo_df = pd.concat([success_df, fail_df], ignore_index=True, sort=False)\n",
    "\n",
    "xref_df = pd.read_table(\n",
    "    'https://raw.githubusercontent.com/dhimmel/disease-ontology/'\n",
    "    '75050ea2d4f60e745d3f3578ae03560a2cc0e444/data/xrefs-prop-slim.tsv')\n",
    "umls_xref_df = xref_df.query('resource == \"UMLS\"')\n",
    "\n",
    "full_df = (repo_df\n",
    " .merge(umls_xref_df, left_on='ind_id', right_on='resource_id')\n",
    " .drop(['resource', 'resource_id'], axis=1)\n",
    ")\n",
    "\n",
    "# Subset data to those which succeeded or which had (by very simplified \n",
    "#   heuristics) a functional reason for failure.\n",
    "pred_df = (\n",
    "    full_df\n",
    "    .query('label == 1 or functional_failure == True')\n",
    ")\n",
    "\n",
    "pred_df.to_csv('repoDB_filtered.tsv', sep='\\t', index=False)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python [conda env:xswap-analysis]",
   "language": "python",
   "name": "conda-env-xswap-analysis-py"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
